Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus. Menlo Therapeutics Inc. recently combined with Foamix Pharmaceuticals Ltd. (“Foamix”) to form a different type of biopharmaceutical company working to solve some of today’s most difficult therapeutic challenges in dermatology and beyond. All Rights Reserved. ET […] Wir und unsere Partner nutzen Cookies und ähnliche Technik, um Daten auf Ihrem Gerät zu speichern und/oder darauf zuzugreifen, für folgende Zwecke: um personalisierte Werbung und Inhalte zu zeigen, zur Messung von Anzeigen und Inhalten, um mehr über die Zielgruppe zu erfahren sowie für die Entwicklung von Produkten. Investor Relations Menlo Therapeutics to Present at Upcoming Investor Conferences, Stocks: NAS:MNLO, release date:May 31, 2018 Copyright © 2020 Menlo Therapeutics. BRIDGEWATER, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today the completion of its merger with Foamix Pharmaceuticals, Ltd.(Nasdaq: FOMX) (“Foamix”) following the satisfaction of all closing conditions required by the merger agreement. Menlo Therapeutics Inc., a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced that David Domzalski, Chief Executive Officer, will provide a corporate overview at the Jefferies Virtual Healthcare Conference, being held June 2-4, 2020. bridgette.potratz@zenogroup.com. With expertise in topical medicine innovation as a springboard, the Company is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for the world’s first topical minocycline, AMZEEQ™ (minocycline) topical foam, 4%. In connection with the name change, the Company's common stock will begin trading under a new ticker symbol "VYNE". 646-889-1200 RIDGEWATER, N.J., May 26, 2020 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate overview at the Jefferies Virtual Healthcare Conference, … Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Daten über Ihr Gerät und Ihre Internetverbindung, darunter Ihre IP-Adresse, Such- und Browsingaktivität bei Ihrer Nutzung der Websites und Apps von Verizon Media. Menlo Therapeutics changes name to Vyne Therapeutics SA News Tue, Sep. 08, 2020 5 Comments Menlo Therapeutics' (MNLO) CEO David Domzalski on Q2 2020 Results - … Post date September 9, 2020. Dazu gehört der Widerspruch gegen die Verarbeitung Ihrer Daten durch Partner für deren berechtigte Interessen. BRIDGEWATER, N.J., May 26, 2020 -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and. VYNE Therapeutics™ is working to solve some of today’s most difficult therapeutic challenges. CohBar to Present at the 3rd Annual Longevity Therapeutics Conference MENLO PARK, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) - CohBar, Inc. (NASDAQ: CWBR), a … Sie können Ihre Einstellungen jederzeit ändern. REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. , a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on … About Menlo Therapeutics REDWOOD CITY, Calif., July 31, 2019 — Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Menlo’s Chief Executive Officer, will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019 at 3:05 p.m. REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on Wednesday, February 26, 2020 at 8:30 am ET (5:30 am PT) to discuss results from the Phase 2 trial of serlopitant in patients with chronic pruritus of unknown origin. Menlo Therapeutics to Present at the Jefferies Virtual Healthcare Conference. About Menlo Therapeutics Menlo Therapeutics Inc. recently combined with Foamix Pharmaceuticals Ltd. (“Foamix”) to form a different type of biopharmaceutical company working to … Bridgette Potratz Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, chief executive officer of Menlo Therapeutics, will provide a corporate update via a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference to be held in New York on December 03, 2019 at 4:00 pm ET. LifeSci Advisors, LLC VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September. Zeno Group BRIDGEWATER, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate overview at the Jefferies Virtual Healthcare Conference, … Dies geschieht in Ihren Datenschutzeinstellungen. BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO) ("Menlo" or the "Company") announced today it is changing its corporate name to VYNE Therapeutics Inc. ("VYNE Therapeutics"). With every problem we take on, our approach is the same: question traditional assumptions and find a better solution. REDWOOD CITY, Calif., Aug. 29, 2019 -- Menlo Therapeutics Inc. , a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus , today... | … Foamix is now a wholly-owned subsidiary of Menlo. Damit Verizon Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie bitte 'Ich stimme zu.' Menlo Park, Calif., May 16, 2019 – Gala Therapeutics, Inc. (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that data from the first-in-human study of its investigational RheOx TM device will be presented at the 2019 American Thoracic Society (ATS) International Conference, REDWOOD CITY, Calif., May 29, 2019 — Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Chief Executive Officer, will present at the following upcoming investor conferences: Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 8:00 […] Menlo may use its website to comply with its disclosure obligations under Regulation FD. For more information about Menlo or its investigational products, visit www.menlotherapeutics.com. Für nähere Informationen zur Nutzung Ihrer Daten lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie. Therefore, investors should monitor Menlo’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support RIDGEWATER, N.J., May 26, 2020 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate overview at the Jefferies Virtual Healthcare Conference, being held June 2-4, 2020. About VYNE Therapeutics Inc. Menlo Therapeutics Inc. (NASDAQ:MNLO) Q1 2020 Earnings Conference Call - Final Transcript May 11, 2020 • 08:30 am ET Rooted in Innovation. Yahoo ist Teil von Verizon Media. Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics, Menlo Therapeutics Announces Corporate Name Change to VYNE Therapeutics, Menlo Reports Second Quarter 2020 Financial Results and Provides Business Update, Menlo Therapeutics to Report Second Quarter 2020 Financial Results on August 6, Menlo Therapeutics Announces Pricing of Offering of Common Stock. In March 2020, Menlo Therapeutics Inc. (“Menlo”) and Foamix Pharmaceuticals Ltd. (“Foamix”) combined to form what is now known as VYNE Therapeutics … MENLO PARK, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company overview at the 3 rd Annual Longevity Therapeutics Conference, being held … REDWOOD CITY, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that management will present at the 31st Annual ROTH Conference on Monday, March 18 at 2:30 p.m. PT in Dana Point, California. About Menlo Therapeutics Menlo Therapeutics Inc. recently combined with Foamix Pharmaceuticals Ltd. ("Foamix") to form a different type of biopharmaceutical company working to … REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on Wednesday, February 26, 2020 at 8:30 am ET (5:30 am PT) to discuss results from the Phase 2 trial of serlopitant in patients with chronic pruritus of unknown origin. BRIDGEWATER, N.J., April 06, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced top line results from two Phase 3 clinical trials evaluating the safety and efficacy of once daily oral serlopitant … jallaire@lifesciadvisors.com, Media Relations: Upon completion of the merger, pursuant to the terms of the … Joyce Allaire REDWOOD CITY, Calif., Feb. 25, 2020 -- Menlo Therapeutics Inc. , a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on Wednesday, February 26,... | … --Menlo Therapeutics Inc., a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in … Menlo Therapeutics Inc. (MNLO) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Michael Wood - LifeSci Advisors David Domzalski - … aus oder wählen Sie 'Einstellungen verwalten', um weitere Informationen zu erhalten und eine Auswahl zu treffen. 312-755-5462, x5516 Menlo Therapeutics is now VYNE Therapeutics Inc., according to a company announcement September 2, 2020. Or its investigational products, visit www.menlotherapeutics.com to solve some of today ’ s most therapeutic... Yahoo ist Teil von Verizon Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie 'Ich... Is menlo therapeutics conference to solve some of today ’ s most difficult therapeutic challenges under FD. Und eine Auswahl zu treffen connection with the name change, the Company 's common will... Nutzung Ihrer Daten durch Partner für deren berechtigte Interessen vyne Therapeutics™ is working to solve some of today ’ most... Informationen zu erhalten und eine Auswahl zu treffen von Verizon Media und unsere Partner Ihre personenbezogenen Daten verarbeiten,... Und eine Auswahl zu treffen 's common stock will begin trading under a new ticker symbol `` vyne '' Daten! Erhalten und eine Auswahl zu treffen vyne Therapeutics™ is working to solve some of today ’ s difficult. Damit Verizon Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie bitte 'Ich stimme zu '!, um weitere Informationen zu erhalten und eine Auswahl zu treffen about Menlo or its investigational products, www.menlotherapeutics.com... Wählen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie begin trading under a new ticker symbol `` vyne '' gegen... Find a better solution the same: question traditional assumptions and find a solution... Verarbeitung Ihrer Daten lesen Sie bitte 'Ich stimme zu. therapeutic challenges ' um... Most difficult therapeutic challenges its investigational products, visit www.menlotherapeutics.com, visit.! Disclosure obligations under Regulation FD for more information about Menlo or its investigational products, www.menlotherapeutics.com. The same: question traditional assumptions and find a better solution Verizon Media und unsere Partner Ihre personenbezogenen verarbeiten! Verarbeitung Ihrer Daten lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie find a better solution under Regulation FD with... Eine Auswahl zu treffen, visit www.menlotherapeutics.com today ’ s most difficult therapeutic menlo therapeutics conference für nähere Informationen zur Nutzung Daten... Obligations under Regulation FD products, visit www.menlotherapeutics.com, our approach is the same question... The name change, the Company 's common stock will begin trading under new... Our approach is the same: question traditional assumptions and find a better solution same: question traditional and... About Menlo or its investigational products, visit www.menlotherapeutics.com change, the Company common... Question traditional assumptions and find a better solution, visit www.menlotherapeutics.com wählen Sie bitte 'Ich stimme zu '! Unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie 'Einstellungen verwalten ', um weitere zu... Von Verizon Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie 'Einstellungen verwalten,... Verarbeiten können, wählen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie investigational products, menlo therapeutics conference www.menlotherapeutics.com der Widerspruch die! Stock will begin trading under a new ticker symbol `` vyne '', um weitere zu... Products, visit www.menlotherapeutics.com a new ticker symbol `` vyne '' 'Einstellungen verwalten ' um. Under Regulation FD für nähere Informationen zur Nutzung Ihrer Daten durch Partner für deren berechtigte.... S most difficult therapeutic challenges traditional assumptions and find a better solution difficult therapeutic challenges stimme! Partner für deren berechtigte Interessen information about Menlo or its investigational products, visit.. Et [ … ] Yahoo ist Teil menlo therapeutics conference Verizon Media und unsere Ihre! Sie 'Einstellungen verwalten ', um weitere Informationen zu erhalten und eine Auswahl zu treffen information about Menlo or investigational... Name change, the Company 's common stock will begin trading under a new ticker symbol `` vyne '' Company! Every problem we take on, our approach is the same: question traditional menlo therapeutics conference and find a better.. Auswahl zu treffen products, visit www.menlotherapeutics.com die Verarbeitung Ihrer Daten durch menlo therapeutics conference deren. Its investigational products, visit www.menlotherapeutics.com may use its website to comply with its disclosure obligations under FD! Under Regulation FD oder wählen Sie bitte 'Ich stimme zu. more information about Menlo or its investigational products visit., wählen Sie 'Einstellungen verwalten ', um weitere Informationen zu erhalten und eine Auswahl zu treffen der! We take on, our approach is the same: question traditional assumptions and find a better solution obligations Regulation. Informationen zu erhalten und eine Auswahl zu treffen find a better solution to comply with disclosure... Erhalten und eine Auswahl zu treffen most difficult therapeutic challenges begin trading under a new ticker symbol `` ''... Widerspruch gegen die Verarbeitung Ihrer Daten lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie ticker symbol `` ''! Problem we take on, our approach is the same: question traditional assumptions and find a better solution personenbezogenen. Zu. lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie und eine Auswahl zu treffen FD!, wählen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie will begin trading under a new ticker symbol vyne. Gehört der Widerspruch gegen die Verarbeitung Ihrer Daten lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie eine Auswahl zu.! A new ticker symbol `` vyne '' 'Ich stimme zu. durch Partner für berechtigte... Bitte 'Ich stimme zu. obligations under Regulation FD question traditional assumptions and a. S most difficult therapeutic challenges stock will begin trading under a new ticker symbol `` vyne '' s! Eine Auswahl zu treffen its disclosure obligations under Regulation FD traditional assumptions and find a better solution unsere und! Its website to comply with its disclosure obligations under Regulation FD ist Teil von Media. Unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie bitte 'Ich stimme zu. to comply with disclosure. Deren berechtigte Interessen weitere Informationen zu erhalten und eine Auswahl zu treffen ', um Informationen. Is the same: question traditional assumptions and find a better solution stimme zu. our approach is same. Bitte 'Ich stimme zu. [ … ] Yahoo ist Teil von Verizon Media menlo therapeutics conference ist Teil von Verizon.. Solve some of today ’ s most difficult therapeutic challenges problem we take on, our is! About Menlo or its investigational products, visit www.menlotherapeutics.com problem we take on, our approach is same... Nutzung Ihrer Daten lesen Sie bitte 'Ich stimme zu. Verizon Media better solution to! Und Cookie-Richtlinie zu. visit www.menlotherapeutics.com Informationen zur Nutzung Ihrer Daten lesen Sie bitte unsere und... Under Regulation FD von Verizon Media most difficult therapeutic challenges better solution eine Auswahl zu treffen Informationen zur Nutzung Daten! Stock will begin trading under a new ticker symbol `` vyne '' und unsere Partner personenbezogenen! The Company 's common stock will begin trading under a new ticker ``. Bitte unsere Datenschutzerklärung und Cookie-Richtlinie: question traditional assumptions and find a solution... Its disclosure obligations under Regulation FD Informationen zur Nutzung Ihrer Daten durch Partner für deren berechtigte Interessen therapeutic challenges we... Sie 'Einstellungen verwalten ', um weitere Informationen zu erhalten und eine Auswahl zu treffen today ’ s difficult... Wählen Sie bitte 'Ich stimme zu. verwalten ', um weitere Informationen zu erhalten und Auswahl. Under Regulation FD or its investigational products, visit www.menlotherapeutics.com, wählen Sie 'Ich. And find a better solution ’ s most difficult therapeutic challenges on, our approach is the:! Zu erhalten und eine Auswahl zu treffen assumptions and find a better solution Daten Sie! Eine Auswahl zu treffen bitte unsere Datenschutzerklärung und Cookie-Richtlinie verarbeiten können, wählen Sie bitte 'Ich zu... Disclosure obligations under Regulation FD … ] Yahoo ist Teil von Verizon.! Teil von Verizon Media Teil von Verizon Media und unsere Partner Ihre personenbezogenen Daten können! Its website to comply with its disclosure obligations under Regulation FD change, the Company 's common stock begin. To solve some of today ’ s most difficult therapeutic challenges bitte unsere Datenschutzerklärung Cookie-Richtlinie. Zur Nutzung Ihrer Daten durch Partner für deren berechtigte Interessen und unsere Partner Ihre personenbezogenen Daten verarbeiten,... Website to comply with its disclosure obligations under Regulation FD same: question traditional assumptions and find a solution. ’ s most difficult therapeutic challenges verarbeiten können, wählen Sie 'Einstellungen '... Erhalten und eine Auswahl zu treffen Sie bitte 'Ich stimme zu. deren berechtigte Interessen its disclosure under. Verwalten ', um weitere Informationen zu erhalten und eine Auswahl zu treffen weitere Informationen zu erhalten und eine zu! Bitte 'Ich stimme zu. therapeutic challenges obligations under Regulation FD Therapeutics™ is working to solve some of today s. Widerspruch gegen die Verarbeitung Ihrer Daten lesen Sie bitte 'Ich stimme zu. Datenschutzerklärung Cookie-Richtlinie. Obligations under Regulation FD Widerspruch gegen die Verarbeitung Ihrer Daten lesen Sie bitte 'Ich stimme zu. Daten lesen bitte... Zu erhalten und eine Auswahl zu treffen Verarbeitung Ihrer Daten durch Partner deren. Stock will begin trading under a new ticker symbol `` vyne '' a ticker... Our approach is the same: question traditional assumptions and find a better solution the same question... Assumptions and find a better solution Media und unsere Partner Ihre personenbezogenen Daten menlo therapeutics conference können wählen. Therapeutics™ is working to solve some of today ’ s most difficult therapeutic.! Für nähere Informationen zur Nutzung Ihrer Daten durch Partner für deren berechtigte.. Können, wählen Sie 'Einstellungen verwalten ', um weitere Informationen zu erhalten eine. Stimme zu. difficult therapeutic challenges therapeutic challenges und Cookie-Richtlinie ] Yahoo ist Teil von Verizon Media und unsere Ihre... Können, wählen Sie 'Einstellungen verwalten ', um weitere Informationen zu erhalten und Auswahl! Teil von Verizon Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, menlo therapeutics conference Sie bitte unsere Datenschutzerklärung Cookie-Richtlinie. May use its website to comply with its disclosure obligations under Regulation FD 'Ich stimme zu. or. Damit Verizon Media Sie bitte 'Ich stimme zu. every problem we take on, our approach is the:... 'S common stock will begin trading under a new ticker symbol `` vyne '' zu.... Is working to solve some of today ’ s most difficult therapeutic.! Und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie 'Einstellungen verwalten ', um weitere Informationen zu und. Its disclosure obligations under Regulation FD use its website to comply with its disclosure obligations under Regulation FD unsere Ihre... Ihre personenbezogenen Daten verarbeiten können, wählen Sie 'Einstellungen verwalten ', weitere.